Acceptable safety of bevacizumab therapy in combination with chemotherapy in patients with advanced lung cancer.

Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that selectively binds to and neutralizes the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) in October 2006 for use in combination with carb...

Full description

Saved in:
Bibliographic Details
Published in:Zhongguo fei ai za zhi 2009-03, Vol.12 (3), p.231-235
Main Authors: Wu, Wei, Xu, Liyan, Liu, Zhe, Zhu, Yunzhong, Shi, Heling, Tang, Junfang, Liu, Zan, Meng, Qiyi, Guo, Lili, Tao, Hong, Li, Mingzhi
Format: Article
Language:Chinese
Subjects:
Angiogenesis
Bevacizumab
Breast cancer
Cancer therapies
Chemotherapy
Colorectal cancer
Health risk assessment
Immunotherapy
Lung cancer
Lung neoplasms
Metastasis
Monoclonal antibodies
Safety
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that selectively binds to and neutralizes the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) in October 2006 for use in combination with carboplatin and paclitaxel for the initial treatment of patients with unresectable, locally advanced, recurrent, or metastatic, nonsquamous, non-small cell lung cancer (NSCLC). The aim of this study is to observe the safety of bevacizumab therapy in combination with chemotherapy in Chinese patients with NSCLC. Patients with advanced non-squamous NSCLC were treated with Bevacizumab 15 mg/kg, d1, repeated every 21 days until PD; Plus paclitaxel 175 mg/m(2), on dl and carboplatin AUC=6 on dl. The cycle was repeated every 21 days. One grade 3 epistaxis was observed in one patient. One grade 4 thrombosis was observed in one patient. 3/4-grade epistaxis and thrombosis was the most significant adverse events. Other adverse ef
ISSN:1009-3419
1999-6187
DOI:10.3779/j.issn.1009-3419.2009.03.006